Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, ...

The global GLP-1 agonists market, valued at USD 19.70 billion in 2024, is projected to grow at a CAGR of 10.20% to reach USD 52.03 billion by 2034. Driven by rising type 2 diabetes and obesity rates, ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

A Bloomberg report has claimed even businesses which have purchased Copilot plans are struggling to convince users to make the switch, with drugmaker Amgen buying a 20,000 user plan, only to have ...

A new report suggests that Microsoft's sales division is struggling to differentiate Copilot from ChatGPT, with customers ...

Cantor Fitzgerald reaffirmed a neutral rating on Amgen, setting a $305 price target for the medical research firm. Despite ...